Ray Therapeutics’ gene therapy is independent of the causative genes driving inherited vision disorders, which CEO Paul Bresge says is important for reaching a broad patient population. Rare disease retinitis pigmentosa is the first disease target, but the startup also plans to test its approach in more prevalent eye disorders.
Spark Therapeutics just bought out Irish gene therapy outfit Genable Technologies - with whom it's been collaborating since 2014 - for about $15 million in stock.
Discover Houston's best orthopedic surgery centers and what features — from personalized treatment plans to rehabilitation services — make these top providers stand out in their industry.
It's tough to detect macular degeneration until it's gotten pretty serious. Pennsylvania startup Maculogix has a device that picks up on signs early.